Our Products
Our Products

Poze G

Poze G

Generic:

Glitazone & S-Urea Combs

 

Therapeutic Class:

Antidiabetic

 

Composition:

Poze G Tab 30 mg/ 2 mg: 
Each tablet contains 30 mg pioglitazone hydrochloride with 2 mg
glimepiride.

Poze G Tab 30 mg/ 4 mg: 
Each tablet contains 30 mg pioglitazone hydrochloride with 4 mg
glimepiride.

 

Description:

Poze G tablets contain two oral antihyperglycemic agents used in the management of type 2 diabetes: pioglitazone hydrochloride and glimepiride. Pioglitazone hydrochloride acts primarily by decreasing insulin resistance. It improves sensitivity to insulin in muscle and adipose tissue and inhibits hepatic gluconeogenesis. It reduces circulating insulin levels and improves glycemic control. Glimepiride is an oral
glucose-lowering drug of the sulphonylurea class, which acts by increasing
the release of insulin from the pancreatic beta cells.

 

Indications:

Poze G is indicated as an
adjunct to diet and exercise as a once-daily combination therapy to improve
glycemic control in patients with type 2 diabetes who are already treated
with a combination of pioglitazone and a sulfonylurea or whose diabetes is
not adequately controlled with a sulfonylurea alone, or for those patients
who have initially responded to pioglitazone alone and require additional
glycemic control.

 

Dosage:

Poze G tablets are available as a 30 mg pioglitazone plus 2 mg glimepiride or a 30 mg pioglitazone plus 4 mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45 mg and the maximum recommended daily dose for glimepiride is 8 mg. Poze G should therefore not be given more than once daily at any of the tablet strengths.   

 

General:

The use of antihyperglycemic therapy in the management of type 2 diabetes should be individualized on the basis of effectiveness and tolerability.

Dosage Recommendations:

Selecting the starting dose of Poze G should be based on the patient’s current regimen of pioglitazone and/or sulfonylurea. It is recommended that a single dose of Poze G be administered once daily with the first main meal.

Starting dose for patients currently on glimepiride monotherapy:

Based on the usual starting dose of pioglitazone (15 mg or 30 mg daily), Poze G may be initiated at 30 mg/2 mg or 30 mg/4 mg tablet strengths once daily, and adjusted after assessing adequacy of therapeutic response.

Starting dose for patients currently on pioglitazone monotherapy:

Based on the usual starting doses of glimepiride (1 mg or 2 mg once daily), and pioglitazone 15 mg or 30 mg, Poze G may be initiated at 30 mg/2 mg once daily, and adjusted after assessing adequacy of therapeutic response.

Starting dose for patients switching from combination therapy of pioglitazone plus glimepiride as separate tablets:

Poze G may be initiated with 30 mg/2 mg or 30 mg/4 mg tablet strengths based on the dose of pioglitazone and glimepiride already being taken. Patients who are not controlled with 15 mg of pioglitazone in combination with glimepiride should be carefully monitored when switched to Poze G.

Maximum Recommended Dose:

Poze G tablets are available as a 30 mg pioglitazone plus 2 mg glimepiride or a 30 mg pioglitazone plus 4 mg glimepiride formulation for oral administration. The maximum recommended daily dose for pioglitazone is 45 mg and the maximum recommended daily dose for glimepiride is 8 mg. Poze G should therefore not be given more than once daily at any of the tablet strengths. 

 

 

Presentations:

  • Poze G 30 mg/ 2 mg is available in 14’s
  • Poze G 30 mg/ 4 mg is available in 14’s